Javascript must be enabled to continue!
Proof of concept: Molecular prediction of schizophrenia risk
View through CrossRef
Key PointsQuestionTo what extent do global polygenic risk scores (PRS), molecular pathway-specific PRS, complement component (C4) gene expression, MHC loci, sex, and ancestry jointly contribute to risk for schizophrenia-spectrum disorders (SZ)?FindingsGlobal polygenic risk for schizophrenia, sex, and their interaction most robustly predict risk in a classification and regression tree model, with highest risk groups having 50/50 chance of SZ.MeaningPsychometric risk indicators, such as prodromal symptom assessments, may be enhanced by the examination of genetic risk metrics. Preliminary results suggest that of genetic risk metrics, global polygenic information has the most potential to significantly aide in the prediction of SZ.AbstractImportanceSchizophrenia (SZ) has a complex, heterogeneous symptom presentation with limited established associations between biological markers and illness onset. Many (gene) molecular pathways (MPs) are enriched for SZ signal, but it is still unclear how these MPs, global PRS, major histocompatibility complex (MHC) complement component (C4) gene expression, and MHC loci might jointly contribute to SZ and its clinical presentation. It is also unclear whether sex or ancestry interacts with these metrics to increase risk in certain individuals.ObjectiveTo examine multiple genetic metrics, sex, and their interactions as possible predictors of SZ risk. Genetic information could aid in the clinical prediction of risk, but it is still unclear which genetic metrics are most promising, and how sex interacts with genetic risk metrics.Design, Setting, and ParticipantsTo examine molecular risk in a proof-of-concept study, we used the Wellcome Trust case-control cohort and classified cases as a function of 1) polygenic risk score (PRS) for both whole genome and for 345 implicated molecular pathways, 2) predicted C4 expression, 3) SZ-relevant MHC loci, 4) sex, and 5) ancestry.Main Outcomes and MeasuresPRSs, C4 expression, SZ-relevant MHC loci, sex, and ancestry as joint risk factors for SZ.ResultsRecursive partitioning yielded 15 molecular risk classes and retained as significant psychosis classifiers only sex, genome-wide SZ polygenic risk, and one MP PRS. Sex was the most robust classifier in a stepwise regression, and there was a significant interaction of sex with SZ PRS on case status, suggesting males have a lower polygenic risk threshold. By down-sampling case proportion to 1% and 1.4% population base rates in males and females, respectively, high-risk subtypes defined by this model had roughly a 52% odds of developing SZ (individuals with SZ PRS elevated by 2.6 SDs; incidence = 51.8%).Conclusions and RelevanceThis proof-of-concept suggests that global SZ PRS, sex, and their interaction are robust predictors of risk and that males have a lower PRS threshold for onset. Implications for the integration of these metrics with psychometrically-identified risk are discussed.
Title: Proof of concept: Molecular prediction of schizophrenia risk
Description:
Key PointsQuestionTo what extent do global polygenic risk scores (PRS), molecular pathway-specific PRS, complement component (C4) gene expression, MHC loci, sex, and ancestry jointly contribute to risk for schizophrenia-spectrum disorders (SZ)?FindingsGlobal polygenic risk for schizophrenia, sex, and their interaction most robustly predict risk in a classification and regression tree model, with highest risk groups having 50/50 chance of SZ.
MeaningPsychometric risk indicators, such as prodromal symptom assessments, may be enhanced by the examination of genetic risk metrics.
Preliminary results suggest that of genetic risk metrics, global polygenic information has the most potential to significantly aide in the prediction of SZ.
AbstractImportanceSchizophrenia (SZ) has a complex, heterogeneous symptom presentation with limited established associations between biological markers and illness onset.
Many (gene) molecular pathways (MPs) are enriched for SZ signal, but it is still unclear how these MPs, global PRS, major histocompatibility complex (MHC) complement component (C4) gene expression, and MHC loci might jointly contribute to SZ and its clinical presentation.
It is also unclear whether sex or ancestry interacts with these metrics to increase risk in certain individuals.
ObjectiveTo examine multiple genetic metrics, sex, and their interactions as possible predictors of SZ risk.
Genetic information could aid in the clinical prediction of risk, but it is still unclear which genetic metrics are most promising, and how sex interacts with genetic risk metrics.
Design, Setting, and ParticipantsTo examine molecular risk in a proof-of-concept study, we used the Wellcome Trust case-control cohort and classified cases as a function of 1) polygenic risk score (PRS) for both whole genome and for 345 implicated molecular pathways, 2) predicted C4 expression, 3) SZ-relevant MHC loci, 4) sex, and 5) ancestry.
Main Outcomes and MeasuresPRSs, C4 expression, SZ-relevant MHC loci, sex, and ancestry as joint risk factors for SZ.
ResultsRecursive partitioning yielded 15 molecular risk classes and retained as significant psychosis classifiers only sex, genome-wide SZ polygenic risk, and one MP PRS.
Sex was the most robust classifier in a stepwise regression, and there was a significant interaction of sex with SZ PRS on case status, suggesting males have a lower polygenic risk threshold.
By down-sampling case proportion to 1% and 1.
4% population base rates in males and females, respectively, high-risk subtypes defined by this model had roughly a 52% odds of developing SZ (individuals with SZ PRS elevated by 2.
6 SDs; incidence = 51.
8%).
Conclusions and RelevanceThis proof-of-concept suggests that global SZ PRS, sex, and their interaction are robust predictors of risk and that males have a lower PRS threshold for onset.
Implications for the integration of these metrics with psychometrically-identified risk are discussed.
Related Results
T78. MORTALITY IN PATIENTS WITH SCHIZOPHRENIA ADMITTED FOR INCIDENT ISCHEMIC STROKE: A POPULATION-BASED COHORT STUDY
T78. MORTALITY IN PATIENTS WITH SCHIZOPHRENIA ADMITTED FOR INCIDENT ISCHEMIC STROKE: A POPULATION-BASED COHORT STUDY
Abstract
Background
Evidence shows that schizophrenia is associated with increased incidence of cardiovascular diseases (CVD), i...
T176. INSIGHTS INTO THE ROLE OF ORAL AND GUT MICROBIOME IN THE PATHOGENESIS OF SCHIZOPHRENIA
T176. INSIGHTS INTO THE ROLE OF ORAL AND GUT MICROBIOME IN THE PATHOGENESIS OF SCHIZOPHRENIA
Abstract
Background
The role of oral and gut microbiomes in the pathogenesis of schizophrenia has recently come to light with th...
P3627Characteristics and outcomes following myocardial infarction in patients with schizophrenia
P3627Characteristics and outcomes following myocardial infarction in patients with schizophrenia
Abstract
Background
Patients with schizophrenia are a high-risk population due to a high prevalence of cardiovascular risk facto...
Protective Effect of Being Born in Autumn Against Schizophrenia or Schizoaffective Disorder
Protective Effect of Being Born in Autumn Against Schizophrenia or Schizoaffective Disorder
Objective: Birth season, one of the environmental factors in the etiology of schizophrenia, has been considered as a risk factor and various studies have been conducted. Some studi...
On free proof and regulated proof
On free proof and regulated proof
Free proof and regulated proof are two basic modes of judicial proof. The system of ‘legal proof’ established in France in the 16th century is a classical model of regulated proof....
Oscillatory traveling waves reveal predictive coding abnormalities in schizophrenia
Oscillatory traveling waves reveal predictive coding abnormalities in schizophrenia
AbstractThe computational mechanisms underlying psychiatric disorders are hotly debated. One hypothesis, grounded in the Bayesian predictive coding framework, proposes that schizop...
Low-concentration sevoflurane inhalation in treating MK801-induced schizophrenia like disease in mice and a feasibility study of schizophrenia patients
Low-concentration sevoflurane inhalation in treating MK801-induced schizophrenia like disease in mice and a feasibility study of schizophrenia patients
Abstract
GABAergic deficits have been considered to associate with the pathophysiology of schizophrenia and hence GABA receptor subtype A (GABAARs) modulators may have ther...
Core of Schizophrenia: Estrangement, Dementia or Neurocognitive Disorder?
Core of Schizophrenia: Estrangement, Dementia or Neurocognitive Disorder?
<i>Background:</i> The recent literature frequently represents schizophrenia as a deteriorating neurocognitive process similar to organic degenerative dementia. <i&g...

